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Delaying the oocyte maturation trigger by one
day leads to a higher metaphase II oocyte yield in
IVF/ICSI: a randomised controlled trial
Frank Vandekerckhove1*, Jan Gerris1, Stijn Vansteelandt2, An De Baerdemaeker1, Kelly Tilleman1
and Petra De Sutter1
Abstract
Background: The negative impact of rising progesterone levels on pregnancy rates is well known, but data on
mature oocyte yield are conflicting. We examined whether delaying the oocyte maturation trigger in IVF/ICSI
affected the number of mature oocytes and investigated the potential influence of serum progesterone levels in
this process.
Methods: Between January 31, 2011, and December 31, 2011, 262 consecutive patients were monitored using
ultrasound plus hormonal evaluation. Those with > =3 follicles with a mean diameter of > =18 mm were divided
into 2 groups depending on their serum progesterone levels. In cases with a progesterone level < = 1 ng/ml, which
was observed in 59 patients, 30-50% of their total number of follicles (only counting those larger than 10 mm) were
at least 18 mm in diameter. These patients were randomised into 2 groups: in one group, final oocyte maturation
was triggered the same day; for the other, maturation was triggered 24 hours later. Seventy-two patients with
progesterone levels > 1 ng/ml were randomised in the same manner, irrespective of the percentage of larger
follicles (> = 18 mm). The number of metaphase II oocytes was our primary outcome variable. Because some
patients were included more than once, correction for duplicate patients was performed.
Results: In the study arm with low progesterone (<= 1 ng/ml), the mean number of metaphase II oocytes (+/−SD)
was 10.29 (+/−6.35) in the group with delayed administration of the oocyte maturation trigger versus 7.64 (+/−3.26)
in the control group. After adjusting for age, the mean difference was 2.41 (95% CI: 0.22-4.61; p = 0.031). In the
study arm with elevated progesterone (>1 ng/ml), the mean numbers of metaphase II oocytes (+/−SD) were 11.81
(+/−9.91) and 12.03 (+/−7.09) for the delayed and control groups, respectively. After adjusting for PCOS (polycystic
ovary syndrome) and female pathology, the mean difference was −0.44 (95% CI: −3.65-2.78; p = 0.79).
Conclusions: Delaying oocyte maturation in patients with low progesterone levels yields greater numbers of
mature oocytes.
Trial registration: B67020108975 (Belgian registration) and NCT01980563 (ClinicalTrials.gov).
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Background
Various ultrasound and hormonal criteria have been used
to determine the moment to trigger oocyte maturation in
IVF/ICSI cycles. Historically, the moment for triggering
oocyte maturation has been based on follicle diameters
that were measured using ultrasound and levels of serum
estradiol [1,2]. A Cochrane review [3] stated that the use
of sonographic criteria alone might be sufficient but that
the simultaneous determination of serum estradiol is still
recommended as long as large randomised controlled tri-
als have not shown that the incidence of ovarian hyper-
stimulation syndrome is equal in both groups. Combined
monitoring was recommended as "a precautionary good
practice point". These findings were mainly gathered in
agonist protocols.
The decision to advance trigger oocyte maturation by
24 hours did not seem to have a positive effect on the
probability of pregnancy in an antagonist protocol [4].
Irrespective of the use of an agonist or an antagonist
for suppression, we tested whether the protocol of
Garcia-Velasco et al. [5], in which oocyte maturation is
triggered as soon as 3 follicles reach diameters of
18 mm, could be adapted further. These authors used it
to compare ovarian steroid production when either an
agonist or an antagonist was used. We also applied a
uniform protocol for monitoring and hypothesised that
delaying the administration of the trigger for 24 hours
would result in a higher yield of mature oocytes, which
served as our primary outcome variable. To evaluate
whether this modification had any consequences on
pregnancy rates or pregnancy outcomes, these variables
were further evaluated as secondary outcomes. This ran-
domised controlled trial was performed in patients with
normal serum progesterone levels.
It is known that high progesterone levels (>1.5 ng/ml)
have a deleterious effect on the endometrium and, thus,
on pregnancy rates [6]. When progesterone levels are
slightly elevated (>1 ng/ml), it can be difficult to decide
whether to continue the stimulation procedure for one
more day. A randomised controlled trial was carried out
on this group of patients to evaluate the number of ma-
ture oocytes at retrieval as the primary outcome variable.
Pregnancy rates and outcomes were important second-
ary variables.
Methods
This study was approved by the Ethical Committee of
the Ghent University Hospital (B67020108975) and as a
clinical trial internationally (NCT01980563 at Clinical-
Trials.gov). It was part of a larger prospective trial in a
single university hospital (Gent, Belgium) that compared
cycle monitoring for IVF/ICSI in two parallel control
groups: those with ultrasound monitoring versus those
with combined monitoring (ultrasound plus hormonal
monitoring). Between January 31, 2011, and December
31, 2011, 262 consecutive patients from the latter group
were eligible for the present trial.
Inclusion criteria were the presence of both ovaries and
being a female less than 45 years of age. Patients with
ovarian cysts at the start of the ovarian stimulation pro-
cedure were excluded. Ovarian reserve was determined by
measuring anti-Müllerian hormone (AMH) before starting
treatment (Immunotech, Beckman Coulter Company,
Brea, CA, USA).
Various protocols for controlled ovarian hyperstimulation
were applied. Either recombinant FSH (Gonal F®, Merck
Serono, Geneva, Switzerland) or urinary FSH (Menopur®,
Ferring Pharmaceuticals, Saint-Prex, Switzerland) was used
with daily doses between 150 and 300 U, dependent on age,
anti-Müllerian hormone (AMH) levels and previous re-
sponse, if applicable. In the agonist group, 0.1 mg triptore-
lin (Decapeptyl®, Ipsen, Paris, France) was administered
subcutaneously for 7 days starting on cycle day 1, and go-
nadotrophins were started on cycle day 3. In the antagonist
group, a fixed protocol was used: gonadotrophins were
started on cycle day 3, and 0.25 mg cetrorelix (Cetrotide®,
Merck Serono, Geneva, Switzerland) was injected subcuta-
neously as a daily dose from the 6th day of stimulation until
the day of oocyte maturation triggering. After 1 week of
stimulation with gonadotrophins, a first ultrasound moni-
toring session was planned. Serum levels of estradiol, LH
and progesterone were determined simultaneously. All
samples were analysed with ECLIA (Modular E170, Roche,
Vilvoorde, Belgium). The inter- and intra-assay coefficients
of variability for the progesterone assay were 3.46–6.71%
and 1.1–7.0%, respectively. The cut-off for the sensitivity of
the test (minimal detectable level) was 0.15 ng/ml. Depend-
ing on the findings, patients were scheduled for additional
monitoring every 1 or 2 days. As soon as three follicles
reached a diameter of at least 18 mm, patients were divided
into two groups: those with serum progesterone > 1 ng/ml
and those with a low progesterone level, defined as ≤ 1 ng/
ml. The results of the individual monitoring of the patients
were centralised and discussed at a daily staff meeting. All 6
staff members who were performing monitoring enrolled
patients equally.
When the serum progesterone level was > 1 ng/ml, pa-
tients were randomised (single blinded). They received 5000
U of human chorionic gonadotrophin (hCG) (Pregnyl®,
Merck Sharp & Dohme, NJ, USA) on the same day (high
progesterone early [HPE] group) or 24 hours later (high
progesterone late [HPL] group). A computer-generated list
was used, and allocation concealment was performed
by a secretary over the telephone. This procedure was
supervised by a single observer (FV). No further monitor-
ing was planned the day after randomisation into the HPL
group. When more than 3 oocytes were expected, oocytes
were retrieved with a single lumen needle. Flushing through
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a double lumen needle was performed in all other cases. All
laboratory procedures were carried out as previously
described [7]. In cases of ICSI treatment, the number of
mature oocytes was dependent on their morphological
appearance after denudation. In IVF cycles, all oocytes
that were inseminated were classified as mature, as is ac-
ceptable convention per the literature. A maximum of
2 embryos were transferred 3 days after oocyte retrieval.
Luteal support consisted of 600 mg micronised progester-
one (Utrogestan®, Besins Healthcare, Bangkok, Thailand)
that was administered vaginally in three daily doses, start-
ing after oocyte collection, and continued until 2 weeks
after transfer if not pregnant or until a clinical pregnancy
was confirmed by ultrasound.
For patients with a low progesterone level (<1 ng/ml), a
different approach was used. When > 50% of the follicles
were larger than 18 mm, 5000 U of hCG was injected on
the same day. Only follicles of at least 10 mm were
counted to obtain this ratio. If the number of follicles with
a diameter of at least 18 mm was between 30 and 50% of
the total number counted, the patient was randomised.
They received 5000 U of hCG on the same day (low pro-
gesterone early [LPE] group) or 24 hours later (low pro-
gesterone late [LPL] group), and no extra monitoring
procedure was performed the day after randomisation in
the LPL group. Allocation was performed as previously
described. Further treatment was completed as described
above for patients with a progesterone level > 1 ng/ml.
The results of the trial were processed anonymously
by a single observer (FV). The number of metaphase II
oocytes (MII) was our primary outcome variable. Sec-
ondary variables that demonstrate the oocyte yield were
the number of oocytes retrieved, the number of fertilised
oocytes (2PN) and the number of good quality embryos
(GQE) on day 3. Other secondary outcome variables were
defined according to the literature [8]: pregnancy rates
(PR), clinical pregnancy rates (CPR), ongoing pregnancy
rates (OPR) and live birth rates (LBR) as expressed per
cycle; clinical implantation ratios (CIR/E), ongoing im-
plantation ratios (OIR/E) and live birth ratios (LBR/E)
were calculated for each individual embryo that was
transferred.
The sample size calculation for the group with proges-
terone levels ≤ 1 ng/ml was based on a mean yield of
6 mature oocytes (SD = 3) in the LPE group versus 11
(SD = 6) in the LPL group [4,9], resulting in a required
sample size of 15 in each group (Welch’s t-test, 5% signifi-
cance level, 80% power). For patients with high progester-
one levels (>1 ng/ml), we found no comparable data in
the literature as a reference. We therefore decided to in-
clude patients in the HPE and HPL groups concomitantly
with the LPE and LPL groups.
The descriptive analyses in Table 1 were based on
Fisher's exact tests for proportions and Student’s t-tests
for continuous outcomes; when the data were skewed or
contained outliers, the non-parametric Mann–Whitney
Table 1 Descriptive statistics
Variable Prog ≤ 1 ng/ml Prog ≤ 1 ng/ml Prog > 1 ng/ml Prog > 1 ng/ml
hCG day 0 (LPE) hCG day +1 (LPL) hCG day 0 (HPE) hCG day +1 (HPL)
Number of patients [cycles] 20 [28] 31 [31] 28 [36] 25 [36]
Age (years) 34.5 (4.4) 33.5 (4.9) 30.5 (3.8) 31.9 (4.2)
Gravidity 0.9 (1.3) 0.9 (1.7) 0.5 (0.9) 0.8 (1.4)
Parity 0.4 (0.6) 0.4 (0.8) 0.3 (0.6) 0.3 (0.9)
Duration of infertility (years) 3.3 (2.1) 4.3 (1.4) 4.3 (1.9) 5.2 (2.9)
AMH (ng/ml)* 2.7 (2.1 - 5.0) 4.1 (2.5 - 6.2) 4.6 (3.2 - 5.7) 3.0 (2.3 - 5.2)
E2 (pg/ml)* 1460 (956–2150) 1390 (964–2110) 1298 (810–1825) 1130 (866–1978)
Progesteron (ng/ml)* 0.7 (0.5 - 0.9) 0.8 (0.5 - 0.9) 1.5 (1.2 - 1.8) 1.4 (1.2 - 1.6)
Number of embryos transferred 1.25 (0.64) 1.52 (0.72) 1.29 (0.60) 1.28 (0.46)
Female pathology 6/20 10/31 16/28 9/25
Endometriosis 4/20 2/31 7/28 0/25
Ovarian dysfunction 0/20 2/31 3/28 1/25
PCOS 0/20 1/31 0/28 2/25
Male pathology 7/20 12/31 13/28 14/25
Antagonist 17/28 15/31 17/36 19/36
Recombinant FSH 20/28 24/31 28/36 34/36
Experienced performer transfer 20/28 19/31 22/36 22/36
Numbers are expressed as numbers or as means (SD) unless explained differently.
*Numbers are expressed as median (first and third quartile).
p > 0.05 for all variables.
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Patients with 30-50 % of follicles > 18 mm and 
serum progesterone < 1 ng/ml
Patients with serum progesterone > 1 ng/ml
Figure 1 CONSORT flow chart.
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Figure 2 The distribution of follicle diameters in patients with normal serum progesterone (<1 ng/ml).
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U-test was used. To account for correlations between
measurements for women with repeated cycles, all fur-
ther analyses were based on linear and logistic marginal
regression models that were fitted using generalised esti-
mating equations with exchangeable working correla-
tions. Although adjustment for baseline covariates was
not required in view of the randomised study design, ad-
justments for age, PCOS and female pathology were
used to improve precision in some of the linear models.
All tests were performed at the 5% significance level.
Statistical analyses were performed using SPSS, version
21, and R Studio, version 0.97.320.
Subsequent to ending the trial, additional evidence
came to suggest that serum progesterone levels > 1.5 ng/
ml at the moment of triggering oocyte maturation might
lower pregnancy rates. Therefore, we performed an add-
itional comparison of 2 subgroups of patients: those with
low progesterone levels (<1.0 ng/ml; group A) and those
with highly elevated levels (>1.5 ng/ml; group B). Fisher's
exact test and Student's t-test were again used as de-
scribed above.
Results
Seventy-two patients with at least three follicles ≥ 18 mm
had serum progesterone levels > 1 ng/ml. They were ran-
domised into 2 groups (HPE and HPL) of 36 individuals
each. In the HPE group, the oocyte maturation trig-
ger was administered on the same day. In the HPL
group, hCG was injected 24 hours later. In the
remaining cases with low serum progesterone levels
(<1 ng/ml), 59 patients had 30 to 50% of their folli-
cles measuring equal to or greater than 18 mm.
After randomisation, 28 patients were allocated to
the LPE group and received hCG on the same day.
The remaining 31 patients (LPL group) were trig-
gered 24 hours later. All eligible patients were ran-
domised and could be allocated (Figure 1). The data
were analysed after correcting for duplicate patients
in each group.
No important differences were observed between the
LPE and LPL groups and between the HPE and HPL
groups for all controlled variables (Table 1): age of the
female, gravidity, parity, duration of infertility, ovarian
reserve determined by AMH, peak estradiol level, num-
ber of transferred embryos, diagnostic criteria (such as
female pathology, endometriosis, ovarian dysfunction
and PCOS), male pathology, stimulation protocol, num-
ber of cancellations, number of failed fertilisations and
the experience of the physician performing the embryo
transfer.
What is the effect of delaying the oocyte maturation
trigger by 24 hours in patients with low serum
progesterone (<1 ng/ml)?
In Figure 2, the distribution of the follicle diameters in
these patients is illustrated. By waiting 24 hours (LPL
group), we obtained more oocytes and predominantly more
mature ones compared with the LPE group, where hCG
was administered on the same day (Table 2). Multivariate
analysis with correction for the female’s age showed a
Table 2 The influence of delaying oocyte maturation in patients with a normal progesterone level on the yield of
(mature) oocytes, fertilised oocytes and good quality embryos
Day hCG Number included (cycles/[patients]) Oocytes MII 2PN GQE
0 (LPE) 28 [20] 9.36 (3.21) 7.64 (3.26) 5.29 (3.26) 4.32 (2.62)
+1 (LPL) 31 [31] 12.58 (7.62) 10.29 (6.35) 7.48 (5.25) 5.74 (4.61)
Mean difference 2.97 2.41 1.80 1.18
95% CI 0.45 to 5.49 0.22 to 4.61 −0.15 to 3.76 −0.53 to 2.88
P 0.021 0.031 0.071 0.18
Numbers are expressed as means (SD).
Adjusted for age.
Table 3 The influence of delaying oocyte maturation in patients with a normal progesterone level on pregnancy and
pregnancy outcome
Day hCG PR/cycle CPR/cycle OPR/cycle LBR/cycle CIR/E* OIR/E* LBR/E*
0 (LPE) 31.3% 31.3% 27.1% 27.1% 0.27 (0.42) 0.22 (0.40) 0.22 (0.40)
+1 (LPL) 35.5% 29.0% 25.8% 25.8% 0.26 (0.43) 0.24 (0.43) 0.24 (0.43)
Odds ratio 1.24 0.92 1.00 1.00 Mean difference −0.017 0.017 0.017
95% CI 0.40 to 3.86 0.29 to 2.92 0.30 to 3.37 0.30 to 3.37 95% CI −0.23 to 0.20 −0.20 to 0.23 −0.20 to 0.23
P 0.71 0.88 1.00 1.00 P 0.88 0.87 0.87
*Numbers are expressed as means (SD).
Unadjusted.
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significant difference in the number of oocytes (p = 0.021)
and in the number of mature oocytes (p = 0.031) in favour
of the LPL group (Table 2). No statistically significant dif-
ferences were found in the number of fertilised oocytes and
the number of good-quality embryos.
Several secondary variables were evaluated to compare
the pregnancy rates and pregnancy outcomes. No signifi-
cant differences were found between groups LPE and
LPL (Table 3). Multivariate analysis did not influence the
final results.
What is the effect of delaying the oocyte maturation
trigger by 24 hours in patients with high serum
progesterone (>1 ng/ml)?
Figure 3 reveals a non-normal distribution of elevated
progesterone levels. Thirty patients (48 cycles) had
moderately elevated serum progesterone levels (>1 ng/ml
and ≤ 1.5 ng/ml). Levels higher than 1.5 ng/ml were found
in 23 patients (24 cycles). Cases with very high proges-
terone levels (>3 ng/ml) were very scarce (3 patients).
The yield of mature oocytes was not different be-
tween the HPE (hCG administered the same day) and
HPL (hCG administered 24 hours later) groups. Multi-
variate analysis did not affect the results (Table 4). The
other variables (viz., number of oocytes recovered, ferti-
lised oocytes, good quality embryos and all variables
describing implantation and pregnancy rate) were also
comparable (Table 5).
What is the effect of highly elevated serum progesterone
(>1.5 ng/ml)?
We also compared the findings between patients with low
progesterone levels (group A) and patients with very high
progesterone levels (>1.5 ng/ml) (group B) who were
Serum progesterone (ng/ml)
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Figure 3 The distribution of progesterone levels in patients with elevated serum progesterone (>1 ng/ml).
Table 4 The influence of delaying oocyte maturation in patients with an elevated progesterone level on the yield of
(mature) oocytes, fertilised oocytes and good quality embryos
Day hCG Number included (cycles/[patients]) Oocytes MII 2PN GQE
0 (HPE) 36 [28] 14.23 (8.44) 12.03 (7.09) 8.22 (5.84) 6.5 (5.02)
+1 (HPL) 36 [25] 13.06 (10.00) 11.81 (9.91) 7.78 (5.86) 6.2 (4.80)
Mean difference −1.52 −0.44 −0.97 −0.75
95% CI −5.30 to 2.27 −3.65 to 2.78 −3.49 to 1.55 −2.98 to 1.48
P 0.43 0.79 0.45 0.51
Numbers are expressed as numbers or as mean (SD).
Adjusted for PCO and female pathology.
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triggered on the day of the final monitoring (i.e., no delay
of 24 hours). The numbers of (mature) oocytes, fertilised
oocytes and good quality embryos were all significantly
higher in group B. The variables describing implantation
and pregnancy outcome were lower in group B, although
statistical significance was lacking. More data are required
to confirm our findings (Table 6).
Discussion
The effect of increasing progesterone levels
Increasing serum progesterone during stimulation for
IVF/ICSI may have a negative impact on pregnancy
rates. Venetis [10] reviewed this phenomenon and in-
cluded studies with progesterone levels ≥ 0.9 ng/ml. Ini-
tially, this effect was described in only a fraction of the
reports. In a recent systemic review [11], he expanded
and further confirmed his findings. It seemed that a ratio
of progesterone-to-estradiol > 0.48 reduced pregnancy
rates in antagonist cycles and that this ratio was found
to be an independent predictor of pregnancy [12]. The
effect of elevated progesterone levels was higher in pa-
tients with a rather low ovarian response [11]. An emer-
ging progesterone increase could be predicted by the
number of follicles and an increase in serum estradiol
[13]. This possible negative effect was the consequence
of endometrial changes, because it was not described in
oocyte donation programs [14] or when embryos that
were obtained in a cycle with high progesterone were
cryopreserved and subsequently thawed and transferred
[15]. Van Vaerenbergh [16] demonstrated that gene ex-
pression in the endometrium thoroughly changed when
serum progesterone levels were higher than 1.5 ng/ml.
This threshold of 1.5 ng/ml was further used by Bosch
[6], who clearly demonstrated a negative effect on preg-
nancy rates in both agonist and antagonist cycles. Although
our study was not powered to compare implantation and
pregnancy rates, the additional data in Table 6 confirmed
these findings.
The yield of mature oocytes was either not mentioned
or only calculated as a secondary variable in most stud-
ies. Mio [17], Bustillo [18] and Venetis [11] demon-
strated a higher number of retrieved oocytes in cycles
with elevated progesterone levels. The cut off values for
positive progesterone levels differed between studies,
and uniform conclusions were not formulated. In our
own study (Table 4), there was no significant difference
in the number of (mature) oocytes.
From these observations, we may conclude that there
is no evidence that increasing progesterone levels have a
negative effect in cases where eggs are recruited for do-
nation or for further cryopreservation, be it for medical
or non-medical reasons.
Another possibility is that, if rising progesterone levels
are encountered during the stimulation procedure, we
can delay for a few days more to yield a maximum num-
ber of good-quality eggs. They can be fertilised and cryo-
preserved and be used for transfer later on, the so-called
“segmented procedure” [19].
Table 5 The influence of delaying oocyte maturation in patients with an elevated progesterone level on pregnancy
and pregnancy outcome
Day hCG PR/cycle CPR/cycle OPR/cycle LBR/cycle CIR/E* OIR/E* LBR/E*
0 (HPE) 20.7% 20.1% 17.6% 17.6% 0.16 (0.33) 0.15 (0.33) 0.15 (0.33)
+1 (HPL) 31.8% 28.8% 23.2% 23.2% 0.23 (0.38) 0.18 (0.36) 0.18 (0.36)
Odds ratio 1.75 1.61 1.41 1.41 Mean difference 0.063 0.033 0.033
95% CI 0.59 to 5.22 0.54 to 4.78 0.46 to 4.34 0.46 to 4.34 95% CI −0.10 to 0.22 −0.12 to 0.18 −0.12 to 0.18
P 0.31 0.39 0.55 0.55 P 0.44 0.67 0.67
*Numbers are expressed as means (SD).
Unadjusted.
Table 6 The oocyte yield and pregnancy outcome in
subgroups categorized by highly different progesterone
levels
Group A Group B P
Prog ≤ 1
ng/ml D0
Prog > 1,5
ng/ml D0
Number of patients included 28 14
Number of oocytes 9,36 (3,21)* 16,71 (9,93)* 0.02
Number of mature oocytes 7,64 (3,26)* 13,43 (8,36)* 0.03
Number of fertilised oocytes 5,29 (3,26)* 10,00 (6,50)* 0.02
Number of good quality embryos 4,32 (2,62)* 7,93 (5,14)* 0.03
PR/cycle 31.3% 7,14% 0.07
CPR/cycle 31.3% 7,14% 0.07
OPR/cycle 27.1% 7,14% 0.11
LBR/cycle 27.1% 7,14% 0.11
CIR/embryo 0.27 (0.42) 0.07 (0.27) 0.07
OIR/embryo 0.22 (0.40) 0.07 (0.27) 0.16
LBR/embryo 0.22 (0.40) 0.07 (0.27) 0.16
Numbers are expressed as numbers or as means (SD) unless explained differently.
*p < 0.05.
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The importance of follicle diameters
The ultrasound criteria to decide the best moment for
triggering oocyte maturation have always been a point of
discussion.
When no GnRH agonist/antagonist has been used, a
leading follicle diameter of 16 mm or more and a serum
estradiol of at least 600 pg/ml have served as guidelines
for administering 10000 IU hCG [20]. Using a GnRH
agonist—either in a long or short protocol—multiple cri-
teria have been suggested. This can be explained by the
different stimulation protocols that have been used and
the variations in study designs. The leading follicles have
had to reach diameters of 16 to 20 mm in most cases
[1,2,21-28].
In antagonist cycles, most studies have proposed
leading follicle diameters of 16 to 17 mm [4,9,29-31]. It
seems that, in cycles where an antagonist has been
used, the decision has been made somewhat earlier
than in agonist cycles. In 2006, the Brussels GnRH an-
tagonist Consensus Workshop Group stated that the
optimal timing for triggering oocyte maturation when
using a GnRH antagonist protocol needed to be ex-
plored further [32].
In our study, we focused on follicle diameters in se-
lected patients with low progesterone levels (<1 ng/ml).
They all reached the threshold of having a least 3 folli-
cles ≥ 18 mm [5] with 30–50% of them being large
enough. When waiting 24 hours to inject hCG, a larger
number of (mature) oocytes were obtained (Table 2), as
has already been mentioned by others [27].
In our series, we could not confirm a higher pregnancy
rate in the group in which we triggered oocyte matur-
ation 1 day later (Table 3). This confirms the findings by
Tremmelen and Lane [33], who found that advancing or
delaying hCG administration by 1 day from ‘ideal’ had
no adverse impact on IVF treatment outcomes in non-
programmed GnRH antagonist cycles. Again, we must
notice that our study was not powered to compare preg-
nancy rates, so conclusions on cycle outcomes must be
interpreted with caution.
In spite of this, our findings support the idea that a
higher yield of mature oocytes indirectly contributes to a
higher overall productivity rate, as mentioned by Stanger
and Yovich [34].
Conclusions
As soon as three follicles have a diameter ≥ 18 mm, fur-
ther decisions to pinpoint the moment for administering
hCG depend on the progesterone level. If the progester-
one level is higher than 1 ng/ml, delaying the adminis-
tration of hCG by 24 hours has no effect on the number
of mature oocytes. If the progesterone level is ≤ 1 ng/ml
and 30–50% of the follicles have diameters ≥ 18 mm,
delaying oocyte maturation by 24 hours is advised.
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